Diabetes Pipeline Landscape Guide 2021: Key Collaborations, Recent Trends, Emerging Drugs, Novel Technologies

News provided by

Nov 29, 2021, 14:30 ET

DUBLIN, Nov. 29, 2021 /PRNewswire/ -- The "Diabetes - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diabetes R&D. The therapies under development are focused on novel approaches to treat/improve Diabetes.

Emerging Drugs Chapters

This segment of the Diabetes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tirzepatide: Eli Lilly and Company

Tirzepatide is a new once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly and Company. In the recent Phase III SURPASS-4 study, tirzepatide supported the reduction of hemoglobin A1C (HbA1c) in people with type 2 diabetes while also supporting weight loss. Tirzepatide, if approved, could also be a blockbuster, given its ability to improve blood glucose levels and support weight loss.

Other Emerging Drugs

ORMD-0801: Oramed
Ladarixin: Dompe Farmaceutici S.p.A.
Enavogliflozin: Daewoong Pharmaceutical
DBPR-108: CSPC ZhongQi Pharmaceutical Technology

Therapeutic Assessment

This segment of the report provides insights about the different Diabetes drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diabetes

There are approx. 200+ key companies which are developing the therapies for Diabetes. The companies which have their Diabetes drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company.

This report covers around 200+ products under different phases of clinical development like:

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Products have been categorized under various ROAs such as:

Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type

Products have been categorized under various Molecule types such as:

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pipeline Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetes therapeutic drugs key players involved in developing key drugs.

Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetes drugs.

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Diabetes drugs?
How many Diabetes drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetes?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetes therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Diabetes and their status?
What are the key designations that have been granted to the emerging drugs?

Companies Mentioned

Scohia Pharma
Eli Lilly and Company
Boehringer Ingelheim
Genexine
Carmot Therapeutics
Dompe Farmaceutici
REMD Biotherapeutics
Precigen Inc.
Yabao Pharmaceutical Group
Daewoong Pharmaceutical
AstraZeneca
BTB Pharma
Jiangsu Hengrui Medicine
CSPC ZhongQi Pharmaceutical Technology
Tolerion
Caladrius Biosciences
Torrent Pharmaceuticals
Janssen Biotech
Oramed
Boston Therapeutics
Tolerion
ImCyse
Astellas Pharma Inc.
Innovent Biologics
Neuraly, Inc.
Ardelyx
Chia Tai Tianqing Pharmaceutical
Novartis
Ionis Pharmaceuticals
Genexine, Inc.
Ligand Pharmaceuticals
Pfizer
Iltoo Pharma
Imbria Pharmaceuticals
Anelixis Therapeutics
NextCell Pharma
ViaCyte
Avotres Inc.
Vertex Pharmaceuticals
Biocon
Transwell Biotech
Exonate Limited
Aposcience AG
Centrexion Therapeutics
Aurealis
Suzhou Yabao Pharmaceutical

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/za1luz

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets